CN104496879A - Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application - Google Patents
Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application Download PDFInfo
- Publication number
- CN104496879A CN104496879A CN201510017623.4A CN201510017623A CN104496879A CN 104496879 A CN104496879 A CN 104496879A CN 201510017623 A CN201510017623 A CN 201510017623A CN 104496879 A CN104496879 A CN 104496879A
- Authority
- CN
- China
- Prior art keywords
- compound
- diene
- lithium
- hexamethyl
- nitrogen base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Abstract
The invention relates to the field of medicine related to thrombotic diseases, in particular to a nitrile-based benzene and diene fluoro-adamantane contained structure protease activated acceptor-1 (PAR-1) antagonist and a preparation method and an application thereof. A general formula is (img file='DDA0000655737390000011.TIF' wi='751' he='428'/).
Description
Technical field
The present invention relates to the pharmaceutical field relevant to thrombus disease.Specifically, the present invention relates to PAR-1 antagonist of the medicative a kind of nitrile group-containing benzene of thrombotic diseases and diene fluoroadamantane structure and preparation method thereof, containing their pharmaceutical composition and the purposes on treatment thrombotic diseases.
Background technology
Proteinase activated receptors 1 (Protease Activated Acceptor-1, PAR-1) is the novel targets of the antiplatelet class antithrombotic reagent found recently.Proteinase activated receptors 1 is thrombin receptor again, zymoplasm by coagulation cascade activate after by PAR-1 receptor acting in thrombocyte thus activate thrombocyte, cause platelet aggregation thus cause thrombus and blood coagulation.Being rich in platelet component in the thrombus that PAR-1 causes, is the main reason of arterial thrombus.PAR-1 antagonist can block thrombin activation thrombocyte, thus interruption artery thrombosis, may be used for treatment acute coronary artery disease (Acute Coronary Syndrome).Several PAR-1 inhibitor has been had to be in clinical study (Chackalamannil S., Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects, J.Med.Chem., 2006,49 (18), 5389-5403).
Traditional is divided three classes for the medicine preventing and treating thrombotic diseases.The first is anticoagulation class, be divided into direct thrombin inhibitor and indirect thrombin inhibitors, such medicine carrys out inhibition thrombosis by the different links acting on coagulation cascade, has and suppresses various thrombotic effect, as vitamin K antagon and Xa factor inhibitor etc.; Equations of The Second Kind is antiplatelet class, and as COX-1 inhibitor and adp receptor antagonist etc., such medicine is mainly used in preventing and treating arterial thrombus; 3rd class is fibrinolytic agent, is mainly used in the scleroproein formed in lysed blood.
Mostly antiplatelet drug is traditional arterial thrombus protective agents, as clopidogrel and acetylsalicylic acid etc.The shortcoming of these medicines is that bleeding risk is larger.And as the PAR-1 antagonist of newfound antiplatelet class antithrombotic reagent, then there is less bleeding risk, therefore this compounds can as the very promising medicine for the treatment of arterial thrombus.
The invention discloses the PAR-1 antagonist of a kind of nitrile group-containing benzene and diene fluoroadamantane structure, they may be used for the medicine preparing anti-arterial thrombus disease.
Summary of the invention
An object of the present invention is to provide a kind of there is good anti-thrombosis activity the compound with general formula I and pharmaceutically acceptable salt.
Another object of the present invention is to provide preparation and has the compound of general formula I and the method for pharmaceutically acceptable salt thereof.
Another object of the present invention be to provide compound containing general formula I and pharmaceutically acceptable salt as effective constituent, and the medicinal compositions of one or more pharmaceutically acceptable carrier, vehicle or thinners, and the application in treatment arterial thrombus.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The present invention has formula I and has following structural formula:
The method of synthetic compound of formula i:
Compound II per is according to literature method synthesis (US4001223).Compound II per and PPh
3be obtained by reacting quaternary alkylphosphonium salt, then use highly basic process to obtain Wittig reagent, then react with III, the diene obtained uses I
2alltrans diene IV is obtained after process; IV hydrolysis obtains V; V and VI is reaction under condensing agent exists, and obtains product I.
Wherein, described highly basic is selected from positive fourth lithium, isobutyl lithium, tertiary Ding Li, hexamethyl two silicon nitrogen base sodium, hexamethyl two silicon nitrogen base potassium, hexamethyl two silicon nitrogen base lithium, lithium diisopropylamine; Described condensing agent is selected from N, N'-dicyclohexyl carbodiimide, N-ethyl-N'-dimethylin carbodiimide, carbonyl dimidazoles.
The pharmacy acceptable salt of formula I of the present invention, include, but are not limited to the salt formed with various mineral acid example hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, Hydrogen bromide etc., also comprise the salt formed as acetic acid, succsinic acid, toxilic acid, oxysuccinic acid and each seed amino acid etc. with various organic acid.
Compound of Formula I of the present invention has the antagonistic action of PAR-1, can be used as the medicine of effective constituent for the preparation of antithrombotic aspect.The activity of compound of Formula I of the present invention is verified by external model.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.These situations comprise: the physical state of patient, route of administration, age, body weight, individual reaction to medicine, the severity etc. of symptom.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
Embodiment 1
2.46g (10mmol) Compound II per and 2.62g (10mmol) PPh
3be dissolved in the THF of 20mL drying, backflow is spent the night under nitrogen protection.After reaction mixture cool to room temperature, obtain a white opacity solution.Be cooled to-78 DEG C under nitrogen protection, slowly drip the hexane solution of 6.25mL (10mmol, 1.6M) n-BuLi.After dropwising, continue stirring one hour, then drip compound 1.28g (10mmol) III and be dissolved in the solution that 2mL THF makes.After dropwising, reaction mixture is slowly warming up to room temperature, then refluxes 1 hour.Reaction mixture pours in frozen water, stirs, and with the dichloromethane extraction of 50mL × 3, merges extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, adds 0.50g iodine, room temperature for overnight in filtrate.Reaction mixture 100mL 5% hypo solution washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains the sterling of product IV; White solid, ESI-MS, m/z=279 ([M+H]
+).
1.39g (5mmol) compound IV is dissolved in 15mL methyl alcohol, adds the NaOH solution of 1mL 30%, then temperature rising reflux 10 minutes.After reaction mixture cooling, pour in 100mL frozen water, regulate pH=2 with concentrated hydrochloric acid.With the dichloromethane extraction of 50mL × 3, merge extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains the sterling of product V; White solid, ESI-MS, m/z=249 ([M-H]
-).
0.75g (3mmol) compound V and 0.59g (3mmol) compound VI is dissolved in the THF of 5mL drying, adds 0.62g (3mmol) DCC, room temperature for overnight.TLC shows reaction to be completed.After reaction mixture cooling, pour in 100mL frozen water, with the dichloromethane extraction of 50mL × 3, merge extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains product I, white-yellowish solid, ESI-MS, m/z=428 ([M-H]
-).
The preparation of embodiment 2 reference compound D1
For absolutely proving the beneficial effect of the compounds of this invention, applicant describes the following formula: compound D1 (unexposed) found in experimentation, as drug effect reference compound.
Synthetic method is as follows:
2.43g (10mmol) Compound II per and 2.62g (10mmol) PPh
3be dissolved in the THF of 20mL drying, backflow is spent the night under nitrogen protection.After reaction mixture cool to room temperature, obtain a white opacity solution.Be cooled to-78 DEG C under nitrogen protection, slowly drip the hexane solution of 6.25mL (10mmol, 1.6M) n-BuLi.After dropwising, continue stirring one hour, then drip compound 1.28g (10mmol) III and be dissolved in the solution that 2mL THF makes.After dropwising, reaction mixture is slowly warming up to room temperature, then refluxes 1 hour.Reaction mixture pours in frozen water, stirs, and with the dichloromethane extraction of 50mL × 3, merges extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, adds 0.50g iodine, room temperature for overnight in filtrate.Reaction mixture 100mL 5% hypo solution washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains the sterling of product IV; White solid, ESI-MS, m/z=275 ([M+H]
+).
1.37g (5mmol) compound IV is dissolved in 15mL methyl alcohol, adds the NaOH solution of 1mL 30%, then temperature rising reflux 10 minutes.After reaction mixture cooling, pour in 100mL frozen water, regulate pH=2 with concentrated hydrochloric acid.With the dichloromethane extraction of 50mL × 3, merge extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains the sterling of product V; White solid, ESI-MS, m/z=245 ([M-H]
-).
0.74g (3mmol) compound V and 0.52g (3mmol) compound VI-1 is dissolved in the THF of 5mL drying, adds 0.62g (3mmol) DCC, room temperature for overnight.TLC shows reaction to be completed.After reaction mixture cooling, pour in 100mL frozen water, with the dichloromethane extraction of 50mL × 3, merge extraction phase brine It, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, resistates column chromatography purification, obtains the sterling of product D 1; White solid, ESI-MS, m/z=399 ([M-H]
-).
Embodiment 7 extracorporeal platelet aggregation inhibition test
In 96 orifice plates, the platelet aggregation of inducing at TRAP (Glycoprotein) concentrates the pharmacology test carrying out material.The sodium citrate solution of 3.13% is added in advance in syringe, then the blood of suction 20mL healthy volunteer, under 1500g centrifugal 20 minutes, separate being rich in hematoblastic blood plasma (PRP) and processing with the amount of 1 μ L PGE1 solution (ethanolic solns of 500 μ g/mL)/mL PRP.After at room temperature hatching 5 minutes, by its under 1200g centrifugal 20 minutes with except leucocyte-removing.To not transfer in the PP pipe of 15mL with 5mL/ part containing leukocytic PRP in batches, and centrifugally under 3600g make pellet platelets.Then, drain upper plasma, the pellet platelets deriving from 5mL PRP is suspended in again 1mL Tyrode (120mM NaCl, 2.6mM KCl, 12mM NaHCO
3, 0.39mM NaH
2pO
4, 10mM HEPES, 0.35%BSA, 5.5mM glucose, pH=7.4) in, and the platelet count of 3 × 105/ μ L is adjusted to Tyrode.By the 10mM CaCl of this for 13mL cell suspension with 866 μ L
2solution-treated, is drawn in 96 orifice plates with the amount of every hole 120 μ L, in the hole of 96 orifice plates, added 15 μ L material to be tested in advance.At room temperature hatch 30 minutes in dark, add 15 μ L TRAP solution (70-100 μM) as agonist, vibrate 20 minutes at 37 DEG C in SpectraMax, kinetics is noted down under 650nm, calculate the area under curve of negative control (tyrode/DMSO) and positive control (15 μ L agonist/DMSO), and difference is decided to be 100%.Aspirated with the form of serial dilution thing by compound to be tested, measure in duplicate, the same AUC measuring each material concentration, the AUC calculated compared with the control suppresses %.IC is calculated according to 4 parametric equations by nonlinear regression analysis by this suppression %
50value.Following table gives result.
| Compound | The suppression IC of platelet aggregation 50(μM) |
| Compound I | 0.41 |
| Reference compound D1 | 0.94 |
As can be seen from the above table, compound of the present invention all shows good restraining effect in platelet aggregation test.
Claims (4)
1. the compound of general formula I and pharmaceutically acceptable salt thereof,
2. synthesize the method for compound described in claim 1:
Compound II per and PPh
3be obtained by reacting quaternary alkylphosphonium salt, then use highly basic process to obtain Wittig reagent, then react with III, the diene obtained uses I
2alltrans diene IV is obtained after process; IV hydrolysis obtains V; V and VI is reaction under condensing agent exists, and obtains product I.
3. method according to claim 2, wherein said highly basic is selected from positive fourth lithium, isobutyl lithium, tertiary Ding Li, hexamethyl two silicon nitrogen base sodium, hexamethyl two silicon nitrogen base potassium, hexamethyl two silicon nitrogen base lithium, lithium diisopropylamine; Described condensing agent is selected from N, N'-dicyclohexyl carbodiimide, N-ethyl-N'-dimethylin carbodiimide, carbonyl dimidazoles.
4. the compound of Formula I that defines of claim 1 and the pharmaceutically application of acceptable salt in preparation treatment thrombotic medicine thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510017623.4A CN104496879A (en) | 2015-01-13 | 2015-01-13 | Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510017623.4A CN104496879A (en) | 2015-01-13 | 2015-01-13 | Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104496879A true CN104496879A (en) | 2015-04-08 |
Family
ID=52938353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510017623.4A Pending CN104496879A (en) | 2015-01-13 | 2015-01-13 | Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104496879A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332726A (en) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | Pyrrolidine compounds and medicinal utilizaion thereof |
| CN1496361A (en) * | 2001-03-16 | 2004-05-12 | Ĭ��ר���ɷ�����˾ | Phenyl derivatives 3 |
| CN101119967A (en) * | 2005-02-17 | 2008-02-06 | 赛诺菲-安万特 | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique |
| WO2008155335A1 (en) * | 2007-06-19 | 2008-12-24 | Pierre Fabre Medicament | Protease activated receptor-1 antagonists for the treatment of atrial fibrillation |
| CN101472907A (en) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists |
| CN101472894A (en) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists |
-
2015
- 2015-01-13 CN CN201510017623.4A patent/CN104496879A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332726A (en) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | Pyrrolidine compounds and medicinal utilizaion thereof |
| CN1496361A (en) * | 2001-03-16 | 2004-05-12 | Ĭ��ר���ɷ�����˾ | Phenyl derivatives 3 |
| CN101119967A (en) * | 2005-02-17 | 2008-02-06 | 赛诺菲-安万特 | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique |
| CN101472907A (en) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists |
| CN101472894A (en) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists |
| WO2008155335A1 (en) * | 2007-06-19 | 2008-12-24 | Pierre Fabre Medicament | Protease activated receptor-1 antagonists for the treatment of atrial fibrillation |
Non-Patent Citations (1)
| Title |
|---|
| ROBERT LETIENNE,: "Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat", 《BIOCHEMICAL PHARMACOLOGY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104072436B (en) | The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use | |
| CN104098520B (en) | Phenyltriazole schiff base compounds, Preparation Method And The Use | |
| CN104529927B (en) | One class is containing oxadiazoles sulfoxide compound, the Preparation Method And The Use of halogeno-benzene | |
| CN104072438B (en) | Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use | |
| CN104072437B (en) | Disubstituted tetrazole acetophenone compound, Preparation Method And The Use | |
| CN104478782B (en) | One class contains compound and the purposes of alkoxyphenyl radical and diene fluoroadamantane structure | |
| CN104086494B (en) | End disubstituted methyl-triazole schiff bases structural compounds, Preparation Method And The Use | |
| CN104529860B (en) | The compound of a kind of nitrobenzene-containing and diene fluoroadamantane structure and preparation method | |
| CN104072435B (en) | The tetrazole acetophenone compound that two alkyl replaces and purposes | |
| CN104140398B (en) | Compound, the Preparation Method And The Use of methyl-triazole schiff bases class formation | |
| CN104447486B (en) | Diene fluoroadamantane compounds, Preparation Method And The Use | |
| CN104557656B (en) | The compound of Halogen benzene and diene adamantane structure, Preparation Method And The Use | |
| CN104496879A (en) | Nitrile-based benzene and diene fluoro-adamantane contained structure compound and application | |
| CN104447485A (en) | Chemical compound of structure containing nitrile benzene and diene adamantine and preparation method and application thereof | |
| CN104447482A (en) | Compound containing nitrobenzene and diene adamantine structure and preparation method and application of compound | |
| CN104447484B (en) | Containing alkoxyphenyl radical and the compound of diene adamantane structure, Preparation Method And The Use | |
| CN104447483B (en) | Containing aniline and the compound of diene adamantane structure, Preparation Method And The Use | |
| CN104529859A (en) | Compound with aniline and diene fluoro adamantane structure and preparation method and application thereof | |
| CN104478781A (en) | Diene adamantane compound and preparation method and usage thereof | |
| CN104496925B (en) | Diene tetrazole compound, Preparation Method And The Use | |
| CN104513212B (en) | Oxadiazoles sulfoxide compound, the Preparation Method And The Use of one class nitrobenzene-containing | |
| CN104478819B (en) | Diene tetrazole amino benzenes compounds, Preparation Method And The Use | |
| CN104529930B (en) | One class nitrile group-containing Ben oxadiazole sulfoxide compound, Preparation Method And The Use | |
| CN104496927B (en) | Diene tetrazole halobenzene compounds, Preparation Method And The Use | |
| CN104072432A (en) | Compound containing phenyl substituted triazole schiff base structure, as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |
|
| RJ01 | Rejection of invention patent application after publication |